Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-Current Debt (2024 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Non-Current Debt for 2 consecutive years, with $94.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt changed 0.2% year-over-year to $94.8 million, compared with a TTM value of $94.8 million through Dec 2025, changed 0.2%, and an annual FY2025 reading of $94.8 million, changed 0.2% over the prior year.
  • Non-Current Debt was $94.8 million for Q4 2025 at Karyopharm Therapeutics, up from $83.9 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $95.2 million in Q1 2025 and bottomed at $83.9 million in Q3 2025.